Immix Biopharma Reports 95% Complete Response Rate in NEXICART-2 AL Amyloidosis Trial

summarizeSummary

Immix Biopharma reported updated Phase 2 clinical trial results for NXC-201, showing a 95% complete response rate in AL Amyloidosis patients with no relapses observed to date, and plans for a Phase 3 trial in H1 2027.

check_boxKey Events

• High Complete Response Rate Achieved

  All four MRD-negative relapsed/refractory AL Amyloidosis patients announced at ASH 2025 have converted to complete response (CR). The overall CR rate for the first 20 patients in the NEXICART-2 trial is now 95% (19 out of 20 patients).

• Durability and Rapid Response

  No relapses have been observed to date for patients who have reached CR, and all CRs were achieved within one year of follow-up post-dosing. MRD-negativity was achieved within 30 days for all MRD-negative patients.

• Advancing to Phase 3 Trial

  The company plans to initiate a multi-center, randomized Phase 3 trial of NXC-201 in newly diagnosed AL Amyloidosis patients in the first half of 2027.

• Next Clinical Update Expected

  The next update from the ongoing NEXICART-2 clinical trial is expected in late September 2026.

auto_awesomeAnalysis

Immix Biopharma announced highly positive updated clinical trial results for its lead candidate NXC-201 in relapsed/refractory AL Amyloidosis. Achieving a 95% complete response (CR) rate with no observed relapses to date for CR patients, and rapid MRD-negativity, is a significant milestone for a Phase 2 trial, especially for a drug with Breakthrough Therapy Designation. This strong data substantially de-risks the development path and supports the company's plan to initiate a potentially registrational Phase 3 trial in the first half of 2027. The next update is expected in late September 2026.